Abstract P3-10-11: Clinical Significance of Progesterone Receptor and HER2 Status in Estrogen Receptor-Positive, Operable Breast Cancer with Adjuvant Tamoxifen: Consistent Prognostic Impact of HER2 Status Over Time
| Autor: | B-W Park, JH Sohn, S Park, Kang, HC Chung, YW Moon, Ja Seung Koo, HS Park |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Gynecology Cancer Research medicine.medical_specialty business.industry Proportional hazards model medicine.medical_treatment Estrogen receptor Cancer Disease medicine.disease Breast cancer Internal medicine Progesterone receptor medicine Clinical significance skin and connective tissue diseases business Adjuvant |
| Zdroj: | Cancer Research. 70:P3-10 |
| ISSN: | 1538-7445 0008-5472 |
| Popis: | Purpose: To evaluate prognostic factors in estrogen receptor (ER)-positive, operable breast cancer, focusing on the progesterone receptor (PR) and HER2 over time. Patients and Methods: A total of 819 patients with ER-positive, operable breast cancer were enrolled. All received adjuvant tamoxifen. Prognostic value of the PR status and HER2 status was evaluated using Cox regression before and after 5 years post-surgery. Results: PR and HER2 status were inversely correlated (P = .014). PR-negativity was a time-dependent poor prognostic factor for recurrence before 5 years post-surgery (P = .049), but not after 5 years post-surgery (P = .566). However, HER2 overexpression and younger age (35 years or less) were consistent prognostic factors for recurrence over all time periods, whereas N stage and histologic grade, which are known prognostic factors, were no longer informative after 5 years post-surgery, except for N3 disease. Conclusion: In ER-positive, operable breast cancer, the prognostic impact of PR status along with N stage and histologic grade were strong for the first 5 years post-surgery, but disappeared thereafter. However, HER2 overexpression was a consistent poor prognostic factor, suggesting that an alternative adjuvant strategy, possibly involving incorporation of prolonged HER2-targeted therapy should be evaluated for HER2-overexpressing tumors. Figure available in online version. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-10-11. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|